$CERS

CERS Q3'26 Earnings: EPS estimate is (0.01) USD

Cerus Corporation (CERS) is expected to report Q3'26 earnings on November 02. Analysts project revenue of $63.25 million and an EPS of -$0.01. Results will be announced after market close.

Original reporting
Published Oct 30, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CERS Q3'26 Earnings: EPS estimate is (0.01) USD — source image
Decision brief

The 30-second read

$CERSNeutralMed
01

Why it matters

The provided EPS and revenue expectations set a benchmark for traders to calibrate risk ahead of the after-hours print.

02

Market read

This is a pre-earnings setup that can influence positioning into the Nov 2 after-hours release.

03

What to watch

Actual price reaction will depend on guidance, cash burn, and any trial or regulatory updates, none of which are included in this text.

Relevance 4/10Novelty 4/10Timing: ahead of Nov 2 after-hours Q3'26 earnings release

Background

The piece states Cerus Corporation will announce Q3'26 results on Nov 2 after the market closes, with the earnings release time given as 4:01 PM ET.

Company-level read

Ticker impact

$CERSNeutralMedium confidence
Context

Cerus Corporation is scheduled to report Q3'26 results on Nov 2 after the close, with consensus EPS expected at -0.01 USD.

Expected impact

Likely volatility around the after-hours earnings release as the market compares reported results to the stated consensus EPS and revenue estimates.

Evidence & confidence

The article provides a scheduled earnings date and consensus-style EPS and revenue expectations, which can drive pre-earnings positioning and post-release repricing.

Market effects

Limited spillover, but biotech earnings calendars can marginally affect sentiment in medical diagnostics and life sciences around the same window.

Primarily US-focused via after-hours trading around the earnings release.

Low, as the catalyst is company-specific and not a global macro policy release.

Counterpoint

Because the article is only a scheduled earnings preview with consensus figures, it may not change expectations meaningfully versus what traders already know from standard earnings calendars.

Key entities

  • Cerus Corporation

    Subject of the earnings preview, scheduled to report Q3'26 results on Nov 2 after the close.

Related articles

$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.